Healthcare / Medical Instruments & SuppliesASX
$3.19
-0.09 (-2.76%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $20.3M · quality 69.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$952M
P/E
45.5x
↑EV/EBITDA
26.1x
↑ROE
9.8%
↑Gross Margin
78.2%
↑Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+18.4%
FCF CAGR
—
FCF margin
17.7%
FCF / Net income
1.71x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $198.9M · net income $20.7M · FCF $35.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $198.9M | $198.9M | $171.6M | $167.5M | $119.7M |
| Net Income | $20.7M | $20.7M | $13.0M | $19.9M | $3.7M |
| EBITDA | $31.8M | $31.8M | $21.7M | $29.5M | $7.9M |
| EPS | 0.07 | 0.07 | 0.04 | 0.06 | 0.01 |
| Gross Margin | 78.2% | 78.2% | 78.1% | 78.9% | 76.3% |
| Operating Margin | 4.5% | 4.5% | 0.4% | 6.5% | -4.1% |
| Net Margin | 10.4% | 10.4% | 7.6% | 11.9% | 3.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.05 | 0.07 | 0.08 |
| Current Ratio | 6.40 | 6.40 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $35.3M | $35.3M | $20.3M | $19.7M | $-271000.00 |
| Returns | |||||
| ROE | 9.8% | 9.8% | 7.1% | 12.1% | 2.7% |
| Valuation | |||||
| P/E | 45.50 | 45.50 | 70.71 | 69.95 | 316.39 |
| EV/EBITDA | 26.11 | 26.11 | 36.69 | 43.71 | 140.06 |
| P/B | 4.69 | 4.69 | 5.03 | 8.49 | 8.54 |
| Growth & Yield | |||||
| Revenue Growth | 16.0% | 16.0% | 2.4% | 39.9% | — |
| EPS Growth | 59.3% | 59.3% | -35.3% | 432.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
61.7%
EPS terminal req.
$0.28
Spread vs growth
-2.4%
5Y implied EPS CAGR
38.6%
EPS terminal req.
$0.34
Spread vs growth
20.7%
10Y implied EPS CAGR
23.5%
EPS terminal req.
$0.55
Spread vs growth
35.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-27.1%
Start / end P/E
103.6x → 47.4x
EPS bridge
0.04 → 0.07
Residual
-32.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.